Drug Trial Radar · NCT03682601
Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment
Last checked: Nov 19, 2026Latest source record: Jul 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
32
Actual
Start
Aug 30, 2018
Primary completion
Feb 12, 2021
Study completion Feb 13, 2021
Sponsor
- Lead sponsor
- GTO Pharmaceutical, LLCAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 24, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 20 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the use of topical 5 or 10% sinecatechins, a botanical drug derived from green tea for the alleviation of sexual pain in the area around the vaginal opening (the vulvar vestibule), that is a main source of pain during sexual contact or dyspareunia, in postmenopausal women, with vulvovaginal atrophy. Women may or may not be using estrogens. Half of the women will receive the study drug, 5 or 10% sinecatechins and half will receive placebo. In addition to the reduction or elimination of pain upon penetration, women may also experience increase in lubrication, arousal and intensity of orgasm
Conditions
- Sexual Pain Disorders
- Postmenopausal Symptoms
- Vulvovaginal Atrophy
- Female Sexual Dysfunction
- Dyspareunia
- Vulvodynia
- Vestibulodynia
- Arousal Disorders, Sexual
- Genito-Pelvic Pain/Penetration Disorder
- Female Sexual Arousal Disorder
Interventions
5% sinecatechins ointmentDrug
Topical 5% sinecatechins ointment will be applied once daily.
PlaceboDrug
Aquaphor/vehicle
10% sinecatechins ointmentDrug
Topical 10% sinecatechins ointment will be applied three times per week up to once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Numerical Rating Scale for PainTime frame: Numerical Rating Scale for pain was assessed at Visit 1 (initial visit); Visit 2 (at 2 weeks), and Visit 3 (at 4 weeks).
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Lila Nachtigall, M.D.
New York, New York
Miriam Greene, M.D.
New York, New York
Cynthia Krause, M.D.
New York, New York
Janis Enzenbacher, M.D.
Nyack, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.